The genetic screening program for familial hypercholesterolemia (FH) in the Netherlands,
which was embraced by the Dutch Ministry of Health from 1994 to 2014, has led to twenty …

Abstract Purpose of Review We summarize recent advances in the understanding of genetic
testing in familial hypercholesterolemia (FH), the use of expanded FH next-generation …

Although mucopolysaccharidoses (MPS), inherited metabolic diseases from the group of
lysosomal storage diseases (LSD), are monogenic disorders, recent studies indicated that …

Ovarian cancer is a gynecological malignancy characterized with increasing death rate in
the world. It is clinically reported that chemotherapy against ovarian cancer is still found with …

Introduction: The cause of familial hypercholesterolemia (FH) is defect in LDL receptor or
familial defect of apolipoprotein B-100 (FDB) or, rarely, defect in proprotein convertase …

Familial hypercholesterolaemia (FH) is caused by pathogenic variants in LDLR, APOB or
PCSK9. Impaired low‐density lipoprotein (LDL) receptor function leads to decreased LDL …

Inheritance of familial hypercholesterolaemia undoubtedly increases the likelihood that
lipoprotein (a) will be raised. However, in familial hypercholesterolaemia when ASCVD …

Although its economic, cultural and biological importance, many genes haven't been
depicted, sequenced or analyzed to date for Camelus dromedarius. In the present paper, the …

Statins are drugs used for people with abnormal lipid levels (hyperlipidemia) and are among
the best-selling medications in the United States. Thus, the aspects related to the production …

Familial hypercholesterolemia (FH) is a common heritable condition in which mutations of
genes governing cholesterol metabolism result in elevated LDL levels and accelerated …